RxDoctor Payments DataLook up a doctor →

Kenan Arkawi, PA

Medical · Phoenix, AZNPI 1922250612

Payments from drug & device makers

$11,838in general payments, 2019–2025

Across 531 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Sun Pharmaceutical Industries Inc.$1K
  • Johnson & Johnson$829
  • Dermavant Sciences, Inc.$812
  • Pfizer$789
  • Amgen$754
  • plus $5K from 24 others

What the payments were for

  • Consulting fees$6005%
  • Food & beverage$10,49689%
  • Education$7436%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,838 in reported general payments places this provider in the 95th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$279,140
Medicare patients
649
Services billed
5,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$181,041
OtezlaApremilast21$100,098
Dupixent PenDupilumab13$47,017
Dupixent SyringeDupilumab14$46,273
Clobetasol Propionate90$5,889
Ketoconazole270$4,200
Tacrolimus24$3,923
Metronidazole43$3,376
Triamcinolone Acetonide339$2,903
Fluocinonide70$2,737
Fluorouracil34$2,731
Tretinoin14$1,784
Hydroxyzine Hcl60$1,673
Clindamycin Phosphate33$1,207
Doxycycline Monohydrate69$1,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$754$100,09821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 748 medical providers in Arizona.

Other medical in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →